Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

Background A growing body of evidence suggests that atrial fibrillation (AF) is associated
with myocardial infarction (MI). However, incidence and management of MI in AF is still …

Purpose The findings from the observational studies comparing the effectiveness and safety
of non–vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …

The RE-LY study demonstrated the safety and efficacy of dabigatran relative to warfarin for
stroke prevention in non-valvular atrial fibrillation. It is important to further evaluate safety …

Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …

In the RE-LY clinical trial, dabigatran presented a better effectiveness/safety profile when
compared to warfarin. However, clinical trials are not very representative of the real-world …

Background The bleeding risk among patients with atrial fibrillation is higher early after
initiating therapy with vitamin K antagonists (VKAs). Evidence is limited on how prior VKA …

Background Patients with non-valvular atrial fibrillation who are receiving or have been
previously exposed to a vitamin K antagonist could be switched to a non-vitamin K …

Background Signals of an increased risk of myocardial infarction (MI) have been identified
with dabigatran etexilate in randomized controlled trials (RCTs). Methods and Resules We …

Abstract Introduction Novel oral anticoagulants (NOACs) expanded the options for stroke
prevention in atrial fibrillation (AF). Earlier studies comparing their relative effectiveness and …